JP2022537913A5 - - Google Patents

Info

Publication number
JP2022537913A5
JP2022537913A5 JP2021571935A JP2021571935A JP2022537913A5 JP 2022537913 A5 JP2022537913 A5 JP 2022537913A5 JP 2021571935 A JP2021571935 A JP 2021571935A JP 2021571935 A JP2021571935 A JP 2021571935A JP 2022537913 A5 JP2022537913 A5 JP 2022537913A5
Authority
JP
Japan
Application number
JP2021571935A
Other languages
Japanese (ja)
Other versions
JP7640474B2 (ja
JP2022537913A (ja
JPWO2020249979A5 (https=
Filing date
Publication date
Priority claimed from GBGB1910125.2A external-priority patent/GB201910125D0/en
Application filed filed Critical
Publication of JP2022537913A publication Critical patent/JP2022537913A/ja
Publication of JP2022537913A5 publication Critical patent/JP2022537913A5/ja
Publication of JPWO2020249979A5 publication Critical patent/JPWO2020249979A5/ja
Application granted granted Critical
Publication of JP7640474B2 publication Critical patent/JP7640474B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021571935A 2019-06-14 2020-06-15 血管性浮腫の治療 Active JP7640474B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962861758P 2019-06-14 2019-06-14
US62/861,758 2019-06-14
GBGB1910125.2A GB201910125D0 (en) 2019-07-15 2019-07-15 Treatments of angioedema
GB1910125.2 2019-07-15
PCT/GB2020/051441 WO2020249979A1 (en) 2019-06-14 2020-06-15 Treatments of angioedema

Publications (4)

Publication Number Publication Date
JP2022537913A JP2022537913A (ja) 2022-08-31
JP2022537913A5 true JP2022537913A5 (https=) 2023-07-27
JPWO2020249979A5 JPWO2020249979A5 (https=) 2023-07-27
JP7640474B2 JP7640474B2 (ja) 2025-03-05

Family

ID=67700187

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021571935A Active JP7640474B2 (ja) 2019-06-14 2020-06-15 血管性浮腫の治療

Country Status (18)

Country Link
US (1) US20220226293A1 (https=)
EP (1) EP3982961A1 (https=)
JP (1) JP7640474B2 (https=)
KR (1) KR20220024221A (https=)
CN (2) CN113993520A (https=)
AR (1) AR119159A1 (https=)
AU (1) AU2020293616A1 (https=)
BR (1) BR112021024447A2 (https=)
CA (1) CA3142220A1 (https=)
CL (2) CL2021003243A1 (https=)
GB (1) GB201910125D0 (https=)
IL (1) IL288612A (https=)
MA (1) MA56188A (https=)
MX (1) MX2021014558A (https=)
PH (1) PH12021552967A1 (https=)
SG (1) SG11202113375PA (https=)
TW (1) TW202112371A (https=)
WO (1) WO2020249979A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
WO2021028645A1 (en) 2019-08-09 2021-02-18 Kalvista Pharmaceuticals Limited Plasma kallikrein inhibitors
US20250281397A1 (en) 2022-04-27 2025-09-11 Kalvista Pharmaceuticals Limited Formulations of a plasma kallikrein inhibitor
CN116003386B (zh) * 2022-11-20 2024-03-26 药康众拓(北京)医药科技有限公司 一种氘代n-苄基吡啶酮吡唑甲酰胺类化合物、药物组合物和用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5187157A (en) 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
GB9019558D0 (en) 1990-09-07 1990-10-24 Szelke Michael Enzyme inhibitors
SE9301911D0 (sv) 1993-06-03 1993-06-03 Ab Astra New peptide derivatives
US5589467A (en) 1993-09-17 1996-12-31 Novo Nordisk A/S 2,5',N6-trisubstituted adenosine derivatives
GB0205527D0 (en) 2002-03-08 2002-04-24 Ferring Bv Inhibitors
US7429604B2 (en) 2004-06-15 2008-09-30 Bristol Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
JP5322935B2 (ja) 2006-07-31 2013-10-23 アクティベサイト ファーマシューティカルズ インコーポレイティッド 血漿カリクレインの阻害薬
DE102006050672A1 (de) 2006-10-24 2008-04-30 Curacyte Discovery Gmbh Hemmstoffe des Plasmins und des Plasmakallikreins
JP2013121919A (ja) 2010-03-25 2013-06-20 Astellas Pharma Inc 血漿カリクレイン阻害剤
EP2590945B1 (en) 2010-07-07 2014-04-30 The Medicines Company (Leipzig) GmbH Serine protease inhibitors
US20130210809A1 (en) 2010-07-14 2013-08-15 Christelle Boléa Novel 2-amino-4-pyrazolyl-thiazole derivatives and their use as allosteric modulators of metabotropic glutamate receptors
US9290485B2 (en) 2010-08-04 2016-03-22 Novartis Ag N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides
GB2494851A (en) 2011-07-07 2013-03-27 Kalvista Pharmaceuticals Ltd Plasma kallikrein inhibitors
GB201300304D0 (en) 2013-01-08 2013-02-20 Kalvista Pharmaceuticals Ltd Benzylamine derivatives
MY174018A (en) 2013-05-23 2020-03-04 Kalvista Pharmaceuticals Ltd Heterocyclic derivates
EP2886107A1 (en) * 2013-12-17 2015-06-24 ObsEva S.A. Oral formulations of pyrrolydine derivatives
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
GB201609607D0 (en) * 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
HUE057912T2 (hu) * 2017-11-29 2022-06-28 Kalvista Pharmaceuticals Ltd Plazma kallikrein inhibitort tartalmazó dózisformák
GB201721515D0 (en) * 2017-12-21 2018-02-07 Kalvista Pharmaceuticals Ltd Dosage forms comprising a plasma kallikrein inhibtor

Similar Documents

Publication Publication Date Title
BR112023005462A2 (https=)
BR112023012656A2 (https=)
BR112023009656A2 (https=)
JP2022537913A5 (https=)
BR112022026905A2 (https=)
BR112023011738A2 (https=)
BR112023004146A2 (https=)
BR112023006729A2 (https=)
BR102021007058A2 (https=)
BR102020022030A2 (https=)
BR112023016292A2 (https=)
BR112023011610A2 (https=)
BR112023011539A2 (https=)
BR112023008976A2 (https=)
BR102021016200A2 (https=)
BR102021015220A2 (https=)
BR102021014044A2 (https=)
BR102021014056A2 (https=)
BR102021013929A2 (https=)
BR102021012571A2 (https=)
BR102021012230A2 (https=)
BR102021012107A2 (https=)
BR102021012003A2 (https=)
BR102021010467A2 (https=)
BR102021009555A2 (https=)